The trading price of Editas Medicine Inc (NASDAQ:EDIT) remained unchanged on Firday, October 25, and closing at $3.18.
Traders who pay close attention to intraday price movement should know that it fluctuated between $3.17 and $3.355. In examining the 52-week price action we see that the stock hit a 52-week high of $11.69 and a 52-week low of $2.91. Over the past month, the stock has lost -8.88% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Editas Medicine Inc, whose market valuation is $262.29 million at the time of this writing, is expected to release its quarterly earnings report in November. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.75 per share this quarter, however they have predicted annual earnings per share of -2.92 for current year and -2.65 for next year.
From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 29.29M.
On the technical side, indicators suggest EDIT has a 100% Sell on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned EDIT a recommendation rating is 9. Out of them, 3 rate it a Hold, while 6 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Editas Medicine Inc (EDIT) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that EDIT’s price is currently -2.86% off the SMA20 and -10.56% off the SMA50. The RSI metric on the 14-day chart is currently showing 43.38, and weekly volatility stands at 9.46%. When measured over the past 30 days, the indicator reaches 6.66%. Editas Medicine Inc (NASDAQ:EDIT)’s beta value is currently sitting at 1.99, while the Average True Range indicator is currently displaying 0.23. With analysts defining $7-$35 as the low and high price targets, we arrive at a consensus price target of $12 for the trailing 12-month period. The current price is about -120.13% off the estimated low and -1000.63% off the forecast high, based on this estimate. Investors will be thrilled if EDIT’s share price rises to $12, which is the median consensus price. At that level, EDIT’s share price would be -277.36% below current price.
To see how Editas Medicine Inc stock has been performing in comparison to its peers in the industry, here are the numbers: EDIT stock’s performance was 0.00% in the latest trading, and -51.96% in the past year.
An evaluation of the daily trading volume of Editas Medicine Inc (NASDAQ:EDIT) indicates that the 3-month average is 1.86 million. However, this figure has increased over the past 10 days to an average of 1.94.
Currently, records show that 81.77 million of the company’s shares remain outstanding. The insiders hold 0.94% of outstanding shares, whereas institutions hold 67.18%. The stats also highlight that short interest as of 2024-10-15, stood at 18.33 million shares, resulting in a short ratio of 8.19 at that time. From this, we can conclude that short interest is 2816.00 of the company’s total outstanding shares. It is noteworthy that short shares in October were down slightly from the previous month’s figure, which was 18.96 million. However, since the stock’s price has seen -68.61% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
